GLP-1 and health: Beyond weight loss in the Ozempic era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup